GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Tofacitinib (Xeljanz / XR, adult RA, PsA or AS)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug1 sources available - open source summaries, references and comparisons

Xeljanz / Xeljanz XR

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Tofacitinib (Xeljanz / XR, adult RA, PsA or AS) - selected U.S. label sections

Product / population
Adult rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis only. Not ulcerative-colitis induction or pediatric therapy.
Renal measure
Cockcroft-Gault creatinine clearance in mL/min

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal regimen and formulation

For CrCl above 50 through 80, the labeled regimen remains immediate-release 5 mg twice daily or XR 11 mg once daily. At CrCl 30-50 or below 30, use immediate-release 5 mg once daily; patients taking XR should receive the IR product rather than a guessed XR reduction.

Hemodialysis timing

On hemodialysis days, give the dose after dialysis. If it was taken before dialysis, do not give a supplemental dose afterward. These rules do not replace the distinct ulcerative-colitis regimen.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Tofacitinib (Xeljanz / XR, adult RA, PsA or AS) - selected U.S. label sections

Adult rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis only. Not ulcerative-colitis induction or pediatric therapy.

Renal method: Cockcroft-Gault creatinine clearance in mL/min
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeTofacitinib (Xeljanz / XR, adult RA, PsA or AS) - selected U.S. label sections
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13

Product and population scope

Adult rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis only. Not ulcerative-colitis induction or pediatric therapy.

RDM32-tofacitinib-xeljanz-adult-ra-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Tofacitinib (Xeljanz / XR, adult RA, PsA or AS) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis only. Not ulcerative-colitis induction or pediatric therapy.

Renal method: Cockcroft-Gault creatinine clearance in mL/min
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal regimen and formulation

For CrCl above 50 through 80, the labeled regimen remains immediate-release 5 mg twice daily or XR 11 mg once daily. At CrCl 30-50 or below 30, use immediate-release 5 mg once daily; patients taking XR should receive the IR product rather than a guessed XR reduction.

RDM32-tofacitinib-xeljanz-adult-ra-1 · Source locator: 2, adult RA/PsA/AS renal dosage table

Hemodialysis timing

On hemodialysis days, give the dose after dialysis. If it was taken before dialysis, do not give a supplemental dose afterward. These rules do not replace the distinct ulcerative-colitis regimen.

RDM32-tofacitinib-xeljanz-adult-ra-2 · Source locator: 2, adult renal dosage table and dialysis footnote

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13
Retrieved
2026-09-05
DailyMed Set ID
68e3d6b2-7838-4d2d-a417-09d919b43e13
Renal-function method
Cockcroft-Gault creatinine clearance in mL/min
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
f4fb0c8b1f7a162f91ec88f43c5ea515aaee2ea8285f498b50498e9e6bde8234

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
f8f71a3ec52952f82411cca2cfe8e0b32dea28f9310a0d39809e6c4580166e78
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report